Orlistat Accord: Uses, Dosage & Side Effects

What Is Orlistat Accord and What Is It Used For?

Orlistat Accord 120 mg contains orlistat, a gastrointestinal lipase inhibitor. It is used together with a mildly reduced-calorie diet to treat obesity in adults with a body mass index (BMI) of 30 kg/m² or more, and to treat overweight adults (BMI ≥ 28 kg/m²) who also have weight-related health risks such as type 2 diabetes, high blood pressure, or high cholesterol.

Orlistat Accord is a generic version of orlistat, one of the oldest and best-studied medications for long-term weight management. Orlistat was first approved by the United States Food and Drug Administration (FDA) in 1999 and by the European Medicines Agency shortly thereafter. Since then, it has been prescribed to millions of people worldwide and remains listed on the World Health Organization’s Model List of Essential Medicines as a therapy for obesity. Unlike newer injectable weight-loss medications such as GLP-1 receptor agonists, orlistat does not act on the brain or appetite centers — it works exclusively within the gut, which makes it particularly useful for patients who cannot or prefer not to use centrally acting medications.

Obesity is a chronic, relapsing disease that affects more than 650 million adults globally according to the World Health Organization. It is a major driver of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, certain cancers, sleep apnea, and osteoarthritis. Even modest weight loss — in the range of 5–10% of initial body weight — produces measurable improvements in blood pressure, blood glucose, cholesterol profile, and quality of life. Medication such as orlistat is not a replacement for lifestyle change; rather, it is an adjunct that helps patients who struggle to achieve or maintain clinically meaningful weight loss through diet and exercise alone.

Orlistat Accord is manufactured by Accord Healthcare and is therapeutically equivalent to the originator brand Xenical. A lower-strength formulation of orlistat (60 mg, sold under the brand name alli) is available over the counter in several countries for adults with a BMI of 28 or more. The prescription 120 mg strength discussed in this article is the dose used in most clinical trials and approved regulatory indications.

Approved Indications

Orlistat Accord 120 mg is approved in the European Union, United Kingdom, and many other countries for the following indications when combined with a mildly hypocaloric diet:

• Obesity in adults: Treatment of patients with a body mass index (BMI) of 30 kg/m² or more, as an adjunct to diet and lifestyle intervention.
• Overweight adults with risk factors: Treatment of patients with a BMI of 28 kg/m² or more who have associated weight-related risk factors, such as type 2 diabetes, dyslipidemia (high cholesterol or triglycerides), or hypertension.
• Long-term weight maintenance: Supporting maintenance of weight loss after initial dietary success. Studies have shown that orlistat continued for up to four years helps prevent weight regain and reduces progression to type 2 diabetes in high-risk patients.

Treatment should be reviewed after 12 weeks. If a patient has not lost at least 5% of their initial body weight by this point, orlistat is typically discontinued because further response is unlikely. If the patient responds, treatment can be continued for as long as it provides benefit and is well tolerated, with periodic re-evaluation by a physician.

What Orlistat Is Not

It is important to understand what orlistat does not do, because this determines how it fits into a weight-loss strategy:

• Orlistat does not reduce appetite. It does not act on the brain, on hunger hormones such as ghrelin or GLP-1, or on reward pathways. Patients who eat large quantities of low-fat, high-carbohydrate food may not lose weight on orlistat.
• Orlistat does not affect carbohydrate or protein absorption. Calories from sugar, starch, and protein are absorbed normally. Therefore, a balanced reduced-calorie diet remains essential.
• Orlistat is not a quick-fix. Clinically meaningful weight loss develops over months, not days, and the drug is only effective while it is being taken with appropriate dietary support.
• Orlistat is not a substitute for bariatric surgery in patients with severe obesity (BMI ≥ 40 kg/m², or ≥ 35 with comorbidities). Surgery remains the most effective long-term intervention in this group.

The Role of Diet and Lifestyle

Orlistat is only licensed for use in combination with a mildly hypocaloric, nutritionally balanced diet that provides approximately 30% of calories from fat. The daily fat intake should be distributed evenly across three main meals, because a single fat-heavy meal will overwhelm the drug’s capacity and will also produce the most unpleasant gastrointestinal side effects. Practical targets include:

• Daily energy deficit of roughly 500–600 kcal below maintenance requirements
• Approximately 15 g of fat per main meal (total 45–50 g per day for a 2,000-kcal diet)
• Emphasis on whole grains, fruits, vegetables, lean protein, and low-fat dairy
• At least 150 minutes of moderate-intensity physical activity per week, as tolerated
• Structured behavior support such as dietitian consultation, journaling, or group programs

Patients who follow these recommendations not only achieve better weight loss but also experience substantially fewer gastrointestinal side effects, because there is less unabsorbed fat passing through the gut.

What Should You Know Before Taking Orlistat Accord?

Before starting orlistat, your doctor will confirm your BMI, review your medical history for conditions that cause malabsorption, and check for pregnancy, gallbladder or kidney problems, and potential drug interactions. Orlistat is contraindicated in chronic malabsorption syndrome, cholestasis, pregnancy, and breastfeeding. It requires a daily multivitamin and may interact with several commonly prescribed medications.

Orlistat is generally well tolerated, and its safety profile is well characterized after more than two decades of use. However, because it alters how nutrients are absorbed from the gut, it is important to understand the contraindications and precautions before starting treatment.

Contraindications

You must not take Orlistat Accord if any of the following apply:

• Allergy to orlistat or any excipient: Known hypersensitivity to orlistat or to any of the inactive ingredients in the capsule, including microcrystalline cellulose, sodium starch glycolate, povidone, sodium lauryl sulfate, talc, gelatin, indigo carmine (E132), titanium dioxide (E171), edible ink, ammonium hydroxide, propylene glycol, and shellac.
• Chronic malabsorption syndrome: Patients who already have difficulty absorbing nutrients — for example due to celiac disease, Crohn’s disease with extensive small-bowel involvement, short bowel syndrome, or pancreatic insufficiency — should not take orlistat, as it will further reduce nutrient absorption.
• Cholestasis: Orlistat is contraindicated in patients with cholestasis (impaired bile flow), because bile is required to emulsify dietary fat, and cholestasis alters both the safety profile and efficacy of orlistat.
• Pregnancy and breastfeeding: Orlistat is not recommended during pregnancy — weight loss is not advised in pregnancy, and there are no adequate human safety data. Orlistat must also not be used while breastfeeding, as it is not known whether orlistat or its metabolites are excreted in breast milk.
• Children and adolescents under 18: The safety and efficacy of orlistat has not been established in children below 18 years of age, and it is therefore not recommended for this age group outside clinical studies or specialist paediatric obesity services.

Warnings and Precautions

Discuss the following conditions with your doctor before starting Orlistat Accord. These situations may require monitoring, dose adjustment of other medications, or alternative treatment approaches:

• Gallbladder and bile duct disease: Weight loss of any kind — including that induced by orlistat — can increase the risk of developing gallstones. Patients with a history of cholelithiasis should discuss this with their doctor. Orlistat is contraindicated in active cholestasis.
• Liver disease: Rare cases of serious liver injury, including some cases of liver failure, have been reported with orlistat, although a direct causal link has not been established. Report any unexplained symptoms of liver dysfunction to your doctor. Patients with known liver disease should use orlistat with caution.
• Kidney disease and oxalate stones: Orlistat increases oxalate absorption in some patients, which can raise the risk of calcium oxalate kidney stones and, rarely, oxalate nephropathy with impaired kidney function. Patients with a history of kidney stones, chronic kidney disease, or oxalate problems should use orlistat with caution and maintain adequate hydration.
• Type 2 diabetes: Orlistat can improve glycemic control by reducing caloric intake and weight. Patients on insulin or oral antidiabetic drugs should monitor blood glucose closely, as doses may need to be reduced to avoid hypoglycemia as weight decreases.
• Seizure disorders (epilepsy): Rare cases of convulsions have been reported in patients taking orlistat together with antiepileptic medications. Orlistat may reduce absorption of certain antiepileptic drugs. Discuss with your neurologist before starting.
• Anticoagulation with warfarin: Orlistat reduces vitamin K absorption, which can enhance the anticoagulant effect of warfarin and other vitamin K antagonists. INR should be monitored more frequently when orlistat is started or stopped.
• HIV on antiretroviral therapy: Orlistat may reduce absorption of some antiretroviral medications. Virological failure has been reported in rare cases. Discuss with your HIV specialist before starting orlistat.
• Rectal bleeding: Rectal bleeding has been reported with orlistat. Report any new bleeding from the rectum to your doctor so that other causes can be excluded.

Monitoring During Treatment

Regular clinical review is recommended during treatment with orlistat, typically including:

• Body weight and BMI every 4–12 weeks in the first six months
• Review at 12 weeks to decide whether to continue, based on whether at least 5% weight loss has been achieved
• Blood pressure monitoring, particularly in hypertensive patients
• Fasting glucose and/or HbA1c in patients with diabetes or prediabetes
• Lipid profile after initial weight loss stabilizes
• INR in patients on warfarin or other vitamin K antagonists
• Vitamin D and, if indicated, other fat-soluble vitamins in long-term users, particularly those with darker skin, limited sun exposure, or low dietary intake

Pregnancy, Breastfeeding and Fertility

Orlistat Accord must not be used during pregnancy. Weight loss during pregnancy is not recommended under any circumstances, as it can compromise fetal growth and nutrition. Although animal studies have not shown direct teratogenicity, human safety data are insufficient and orlistat has no established indication in pregnancy. Women of childbearing potential should use reliable contraception while taking orlistat, particularly because rapid weight loss may restore ovulation in women with previously irregular cycles and obesity-related anovulation.

Orlistat is also contraindicated during breastfeeding. It is not known whether orlistat or its metabolites pass into human breast milk, and in view of the potential effect on an infant’s fat and fat-soluble vitamin absorption, breastfeeding women should not use the drug.

In addition, patients using oral contraceptives should be aware that, if severe diarrhea occurs while taking orlistat, the absorption of oral contraceptives may be reduced. An additional barrier method such as a condom is recommended during episodes of significant diarrhea.

Driving and Operating Machinery

Orlistat is not expected to affect the ability to drive or operate machinery. It does not cause sedation, dizziness, or impaired cognition. However, as with any change in health or diet, individual responses vary, and patients who experience unusual symptoms should wait until these resolve before driving.

Important Information About Excipients

Orlistat Accord 120 mg hard capsules contain sodium lauryl sulfate and trace amounts of sodium, but each capsule contains less than 1 mmol sodium (23 mg), which is essentially ‘sodium-free.’ Patients with rare hereditary disorders of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should discuss the product leaflet with their pharmacist, as some formulations may contain residual lactose-related excipients.

How Does Orlistat Accord Interact with Other Drugs?

Because orlistat reduces absorption of dietary fat, it can also reduce the absorption of several fat-soluble drugs. The most clinically important interactions involve cyclosporine, levothyroxine, amiodarone, certain antiepileptics (for example lamotrigine, valproate), antiretrovirals, and warfarin. Separate dosing times and additional monitoring are usually required.

Orlistat has very low systemic absorption, so classical pharmacokinetic interactions through the liver enzymes (such as CYP450) are rare. Instead, the most important interactions arise in the gut, where orlistat’s blockade of fat absorption can also interfere with lipophilic co-administered drugs. In some cases, the effect is to lower blood levels of the interacting drug, potentially reducing its efficacy; in others, orlistat-induced reductions in fat-soluble vitamin absorption — especially vitamin K — indirectly alter drug activity, as with warfarin.

Always inform your doctor and pharmacist about all medications you take, including over-the-counter products, dietary supplements, and herbal remedies, before starting orlistat and at every medication review.

Major Interactions

The following interactions are considered clinically significant and may require dose separation, therapeutic drug monitoring, or alternative treatment:

Minor and Additional Interactions

Some additional interactions are less clinically important but still require attention. They often involve fat-soluble vitamins and lipid-soluble co-medications:

What Is the Correct Dosage of Orlistat Accord?

The recommended dose is one 120 mg capsule taken three times daily (360 mg/day) with each main meal containing fat — immediately before, during, or up to one hour after eating. If a meal is missed or contains no fat, skip that dose. Doses above 120 mg three times daily provide no additional benefit and are not recommended.

Orlistat Accord is taken orally with food. The dosing schedule has been consistent across all major international regulatory agencies (EMA, FDA, MHRA) since the product was first approved, and it is based on a large body of randomized controlled trial data.

Adults

How to Take Orlistat Accord

Correct administration is critical for both efficacy and tolerability. Follow these principles carefully:

• Take with a fat-containing meal: Swallow one capsule whole with water, either just before, during, or within one hour of a main meal containing fat. Orlistat must be in the gut at the same time as the fat it is supposed to act on.
• Three main meals per day: Distribute your daily fat intake across three balanced meals. Avoid skipping meals and then “catching up” with a large fatty meal, which overwhelms orlistat’s capacity and triggers strong gastrointestinal side effects.
• Skip the dose if the meal contains no fat: For meals with virtually no fat (for example, a fruit salad or a plain bread roll), there is nothing for orlistat to act on. Taking it anyway provides no benefit and may still cause side effects if fat is consumed later in snacks.
• Limit fat per meal: Aim for no more than about 15 g of fat per main meal (roughly 30% of calories from fat). This both maximizes efficacy and minimizes unpleasant gut symptoms.
• Do not exceed the recommended dose: Doses higher than 120 mg three times daily do not improve results. More capsules per day simply increase the risk of adverse effects without added benefit.
• Combine with a multivitamin: Take one daily multivitamin containing fat-soluble vitamins A, D, E, K, and beta-carotene at bedtime to offset the reduced absorption caused by orlistat.

Children and Adolescents

Orlistat Accord is not recommended for use in children or adolescents under 18 years of age outside specialist paediatric obesity services. Although some clinical studies have evaluated orlistat in adolescents aged 12–16 with severe obesity, results have been mixed and regulatory approval for this age group is limited. In children, obesity treatment focuses primarily on family-based lifestyle interventions, structured dietary programs, and physical activity, supervised by a paediatrician or multidisciplinary team.

Elderly Patients

There are no data suggesting that elderly patients (aged 65 years and older) require a different dose. Pharmacokinetics are not significantly different with age, and no dose adjustment is needed. However, older adults are more likely to have multiple comorbidities and medications, so drug interactions (particularly with warfarin and levothyroxine) and fat-soluble vitamin status should be reviewed carefully before starting. Physical activity recommendations should be individualized to the patient’s mobility and cardiovascular status.

Patients with Liver or Kidney Impairment

Orlistat is minimally absorbed, so hepatic or renal impairment does not generally require a dose adjustment. However:

Missed Dose

If you forget to take a dose of Orlistat Accord and it is within one hour of the end of your meal, take the capsule now with water. If more than one hour has passed since you finished eating, skip the missed dose and take your next capsule with your next main meal. Do not take two capsules together to make up for a missed dose. Missing an occasional capsule has little effect on overall weight-loss progress, but consistent adherence with the three-times-daily schedule is associated with better outcomes.

Overdose

Single doses of up to 800 mg orlistat and multiple doses of up to 400 mg three times daily for 15 days have been studied in healthy-weight and obese subjects without significant adverse events. Acute overdose is therefore unlikely to cause serious harm, but it may increase the frequency of gastrointestinal side effects. If an overdose is suspected, contact your doctor or local poison control center. In children, accidental ingestion should be evaluated by a healthcare professional, particularly if the amount ingested is large or the child is symptomatic.

What Are the Side Effects of Orlistat Accord?

The most common side effects of orlistat are gastrointestinal and directly related to its mechanism of action: oily stools, rectal spotting, flatulence with discharge, urgent bowel movements, and abdominal discomfort. These are worst in the first few weeks and are strongly reduced by keeping dietary fat below about 30% of calories. Serious side effects such as liver injury, severe kidney problems, and severe allergic reactions are rare.

Because orlistat acts entirely within the gut, the overwhelming majority of its side effects are gastrointestinal, reflecting the passage of undigested dietary fat through the bowel. These effects are predictable, dose-related, and diet-related. Patients who adhere to a diet with no more than about 30% of calories from fat (around 15 g per meal) experience markedly fewer and milder effects than those who continue to eat high-fat meals.

Why Do Gastrointestinal Effects Happen — and How to Reduce Them

Understanding why these side effects occur helps patients manage them effectively. When dietary fat is not broken down and absorbed, it passes into the lower gut, where it can alter stool consistency and, because fat is less easily controlled by the anal sphincter, may leak out as oily spotting or escape alongside flatus. The higher the fat content of a meal, the greater the effect. Practical strategies that substantially reduce these effects include:

• Keep fat to about 30% of calories over the day, distributed evenly across three main meals (roughly 15 g of fat per meal for a 2,000 kcal diet)
• Avoid high-fat single meals such as fast food, deep-fried foods, or large portions of full-fat cheese or processed meats
• Read food labels and choose low-fat versions where possible, especially dairy and sauces
• Eat slowly and do not try to “cheat” the drug — the gastrointestinal effects are a reliable feedback mechanism
• Increase fiber gradually to help stabilize stool consistency
• Do not skip doses to ‘save up’ for a fatty meal — that approach increases side effects, not weight loss

Most patients find that gastrointestinal effects are strongest in the first few weeks of treatment and diminish substantially as dietary habits adjust. For the majority of patients, these effects are therefore both a side effect and a behavioral reinforcement of low-fat eating.

Effects on Fat-Soluble Vitamins and Bone Health

Because orlistat reduces absorption of dietary fat, it can also reduce absorption of the fat-soluble vitamins A, D, E, and K, as well as beta-carotene. In clinical trials, average blood levels of these vitamins fell but mostly remained within the normal range; however, some patients developed deficiencies. Long-term use, vegetarian or restrictive diets, dark skin, limited sunlight, and older age all raise the risk. A daily multivitamin supplement containing A, D, E, K, and beta-carotene — taken at bedtime, at least two hours away from the nearest orlistat dose — is strongly recommended.

Vitamin D deficiency in particular can contribute to reduced bone health. Patients planning long-term orlistat therapy, especially postmenopausal women and older adults, should have their serum 25-hydroxyvitamin D checked and corrected if low, and should ensure adequate dietary calcium.

How Should You Store Orlistat Accord?

Store Orlistat Accord below 25°C in the original blister pack to protect the capsules from moisture. Keep out of the sight and reach of children. Do not use after the expiration date printed on the pack.

Correct storage ensures that each capsule remains effective throughout its shelf life and reduces the risk of accidental ingestion by household members for whom the medication is not prescribed.

• Temperature: Store below 25°C. Do not refrigerate or freeze.
• Protect from moisture and light: Keep the capsules in the original blister pack inside the outer carton. Do not transfer to pill organizers that expose them to humidity unless you will use the tablets within a few days.
• Out of reach of children: Orlistat is not indicated in children, and accidental ingestion of large amounts may cause significant gastrointestinal effects. Store the pack in a locked or high cupboard.
• Expiration date: Do not use Orlistat Accord after the expiration date (“EXP”) printed on the blister and carton. The expiration date refers to the last day of the indicated month.
• Disposal: Do not dispose of medications in household waste or wastewater. Return unused capsules to a pharmacy for proper disposal. This protects the environment and prevents accidental exposure.
• Travel: When traveling, keep the medication in its original labeled packaging. Avoid leaving capsules in a hot vehicle or in direct sunlight for prolonged periods.

What Does Orlistat Accord Contain?

Each Orlistat Accord hard capsule contains 120 mg of orlistat as the active ingredient. The capsules are turquoise hard-shell gelatin capsules filled with white or near-white pellets.

Knowing the exact composition of your medication is useful when identifying possible allergens, comparing to other brands of orlistat, and providing information to healthcare professionals.

Active Ingredient

The active substance is orlistat, also known as tetrahydrolipstatin (THL). Each hard capsule contains 120 mg of orlistat. Orlistat is a stable hydrogenated derivative of lipstatin, a natural inhibitor of pancreatic lipases produced by the bacterium Streptomyces toxytricini.

Excipients (Inactive Ingredients)

The other ingredients in Orlistat Accord 120 mg hard capsules typically include:

• Capsule contents: Microcrystalline cellulose, sodium starch glycolate (type A), povidone, sodium lauryl sulfate, and talc
• Capsule shell: Gelatin, titanium dioxide (E171), indigo carmine (E132)
• Printing ink: Shellac, black iron oxide (E172), propylene glycol, ammonium hydroxide, potassium hydroxide (may vary by batch and manufacturing site)

Appearance and Pack Sizes

Orlistat Accord 120 mg hard capsules are turquoise gelatin capsules, typically imprinted with an identifier code, and filled with white to off-white pellets. They are usually supplied in blister packs (PVC/PE/PVdC-aluminium or similar) containing 42, 84, or 90 capsules, though not all pack sizes may be marketed in every country. The 84-capsule pack is commonly used for a 28-day supply at the standard dose of three capsules a day.

Marketing Authorization Holder

Accord Healthcare, with marketing authorizations held in several European Economic Area countries. The product is manufactured and distributed in line with the regulatory standards of the European Medicines Agency (EMA) and the national medicines agencies of the countries in which it is sold. For country-specific product information, always consult the latest patient information leaflet supplied with the pack.

Frequently Asked Questions About Orlistat Accord